WESTMINSTER, Colo.--(BUSINESS WIRE)--Mar 12, 2013--Cerapedics, Inc. today announced that Antony Koblish, president and CEO of privately-held Tela Bio, Inc. and former CEO of Orthovita, Inc., was appointed to the Company’s board of directors.

“Tony has extraordinary industry expertise and operational knowledge and we are delighted that he is joining Cerapedics’ board of directors,” said Jonathan Silverstein, Cerapedics chairman and general partner at OrbiMed Advisors, LLC.

Koblish currently serves as president and chief executive officer of Tela Bio, Inc., a privately-held company located outside Philadelphia, Pennsylvania focused on surgical reconstruction products.

Koblish most recently held the position of president of Stryker Orthobiologics, the business unit formed following the acquisition of Orthovita, Inc. by Stryker Corporation in June 2011 for $316 million. Koblish previously served as president and chief executive officer of Orthovita, Inc. and under his leadership established a 100-person strong direct US sales force and grew revenue from $4 million to approximately $100 million. Prior to being appointed to that position in April 2002, he held various other positions at Orthovita including senior vice president of commercial operations and managing Orthovita’s worldwide marketing division. Prior to his service at Orthovita, Koblish served as director of marketing and product development for the reconstructive specialty group of Howmedica, Inc., a subsidiary of Pfizer, Inc.

Koblish earned a bachelor of science degree in mechanical engineering from Worcester Polytechnic Institute and a master of science degree in mechanical engineering and applied mechanics from the University of Pennsylvania.

“Tony brings a wealth of experience to Cerapedics - from achieving product approvals at FDA to launching and selling innovative biologic products in the orthopedics marketplace. He also has significant insights that come from running a successful market-leading biologics company for over a decade. He will be a tremendous addition to our board,” said Paul Mraz, Cerapedics president and chief executive officer.

“I am honored to join the Cerapedics board of directors and work with this exceptional team,” Koblish said. “Our goal is for Cerapedics to be a leader in the global bone biologics market and I look forward to sharing my knowledge with and contributing to the future direction and growth of Cerapedics.” About Cerapedics, Inc. Cerapedics, a 2012 Colorado Companies to Watch (COCTW) winner, is a medical device company focused on developing and commercializing novel osteobiologic products based upon its proprietary synthetic small peptide (P-15™) technology platform. i-FACTOR bone graft is the only biologic bone graft that utilizes a small peptide as an attachment factor intended to stimulate the natural bone healing process resulting in safe, predictable bone formation at a fraction of the cost of growth factors.

CAUTION: i-FACTOR™ bone graft is not commercially available in the USA. In the USA, i-FACTOR bone graft is an investigational device limited by Federal Law (USA) to investigational use only.